Health Condition 1: F112- Opioid dependence
Conditions
Interventions
Intervention1: BUPRENORPHINE AND GABPENTIN: Tablet Buprenorphine will be given Sub lingually in the dose ranges of 2-16mg based on the tolerability for 14 days and the frequency is divided into one to
the dose will be increased by 300mg every 2-3 days up to a maximum dose of 1200mg per day depending on the tolerability and severity of the patients
the total dose being divided into twice daily and thrice daily dosing which will be given for total duration of 14 days. The dose of Gabapentin will be tapered down by 300mg per day in the next 1 week
Sponsors
Longjam Henbi Devi
Eligibility
Inclusion criteria
Inclusion criteria: 1.Diagnosed with Opioid dependence Syndrome (ODS) as per ICD-10, undergoing Buprenorphine induction. 2. Patients with opioid withdrawal (COWS) 3. Written Informed Consent
Exclusion criteria
Exclusion criteria: 1. The presence of severe mental illness affecting the interview. 2. Co-morbid medical conditions which can contribute to RLS like Iron deficiency anaemia, diagnosed Diabetes Mellitus with peripheral Neuropathy, diagnosed Rheumatic Disease, diagnosed peripheral Neuropathy, diagnosed Parkinson s Disease, Fibromyalgia and Spinocerebellar ataxia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The score of the RLS rating scaleTimepoint: 2 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Severity of RLS symptoms in opioid withdrawal patients. 2. Leeds Sleep Evaluation Questionnaire score. 3. Number of drop outs Timepoint: 1-2 weeks | — |
Countries
India
Contacts
Public ContactDiptadhi Mukherjee
Lokopriya Gopinath Bordoloi Regional Institute of Mental Health
Outcome results
None listed